Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial

Published:2021-12 Issue:12 Volume:6 Page:1015-1024
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Xu Rui-Hua,Zhang Yanqiao,Pan Hongming,Feng Jifeng,Zhang Tao,Liu Tianshu,Qin Yanru,Qin Shukui,Yin Xianli,Liu Baorui,Ba Yi,Yang Nong,Voon Pei Jye,Tanasanvimon Suebpong,Zhou Chan,Zhang Wan Li,Shen Lin

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021;Wang;Cancer Commun,2021

2. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01);Lee;Oncologist,2019

3. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer;Satoh;Gastric Cancer,2015

4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014

5. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity;Lu;J Biol Chem,2003

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

2. Clinicopathological association of CD93 expression in gastric adenocarcinoma;Journal of Cancer Research and Clinical Oncology;2024-08-27

3. Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-08-05

4. Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications;Molecular Cancer;2024-06-29

5. Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Oncology;2024-06-07